INTRABEAM® with other applications

More than 10 years ago INTRABEAM® received both FDA and CE approval for the irradiation of solid tumours in all areas of the body. The INTRABEAM® treatment flexibility results in a wide range of oncological applications in addition to breast cancer therapy. Irradiation during neurosurgical interventions, treatment of colorectal carcinomas, skin cancer or spine metastasisare performed in routine therapy and within the framework of clinical studies in a number of centers around the globe.

Cerebral metastases

Post-operative irradiation of brain tumours and cerebral metastases is often delayed due to wound healing problems and long patient recovery times following the operation. INTRABEAM® offers a cost-efficient and immediate treatment subsequent to a stereotactic biopsy. A substantial number of studies have proven the value of INTRABEAM® in the treatment of brain and cerebral tumours in both children and adults.16, 17, 18, 19, 20, 21

Cerebral metastases

Spinal metastases

For the many cancer patients who develop spinal metastases in the course of their disease, percutaneous kyphoplasty and vertebroplasty are a valuable treatment option. By using intraoperative radiotherapy with INTRABEAM® during kyphoplasty or vertrebroplasty, the metastasis can be sterilised and simultaneously stabilised, a process resulting in reduction of the patient’s pain. It also brings back mobility, significantly enhancing the patient’s quality of life. The first clinical trial experience of this approach has yielded very promising results.15

spinal metastases

Oral cancer

Delivering a boost radiation intraoperatively with INTRABEAM® has potential advantages in the treatment of oral cancers. After resection, the margins of the tumour can be sterilised immediately, which may have a positive impact on local recurrence rate. Additionally, the numerous sensitive structures in this anatomical region can be spared due to the steep fall-off of the low-energy radiation emittedby INTRABEAM®. A geographical miss is unlikely since the applicator can be positioned directly in the tumour bed. First study data have convincingly demonstrated the value of this concept.22

oral cancer

Gastrointestinal cancer

In cancer surgery, the ultimate goal is to remove the tumour completely. However, a complete resection of the tumour is not possible in many patients, meaning that cancer cells remain present in thetumour bed or in neighboring structures. Intraoperative radiotherapy with INTRABEAM® can improve local control of colorectal tumors in cases of local recurrence and local advanced tumours.22 The value of INTRABEAM® has also been demonstrated in the setting of laparoscopic hemicolectomy in patients with colon cancer and gastrectomy in patients with gastric cancer.24, 25

gastrointestinal cancer

Endometrial cancer

In endometrial cancer – the most common malignancy of the female genital tract – the use of INTRABEAM® is also feasible and has some potential advantages compared to most commonly used192Ir high-dose rate (HDR) afterloading, which is highly expensive, given the necessary source changes and the complex radiation protection requirements. By comparison, INTRABEAM® can be used in non-shielded spaces with no radioisotopes involved. First clinical trial evidence has proved that it is possible to create a homogeneous cylindrical dose distribution similar to 192Ir HDR afterloading, suggesting that INTRABEAM® can be used effectively in this common female cancer.26

Endometrial cancer

Skin cancer

The versatility of INTRABEAM® is also displayed in the treatment of skin cancer. Particularly in the treatment of non-melanoma skin cancer, irradiation is an important therapy option, primarily for patients with a high surgical risk. In a prospective study, it was shown that intraoperative radiotherapy with INTRABEAM® was as effective in the management of non-melanoma skin cancer as conventional radiotherapy techniques.27 The well-known advantages of INTRABEAM® – precise radiation delivery, low shielding requirements, and cost effectiveness – also held true for the treatment of skin cancer.

Skin cancer


1 Herskind C, Steil V, Tiefenbacher U et al. Radiobiologic aspects of intraoperative radiotherapy (IORT) with isotropic low-energy X-rays for early-stage breast cancer. Radiat Res 2005; 163: 208–2152

2 Marthinsen AB, Gisetstad R, Danielsen S et al. Relative biological effectiveness of photon energies used in brachytherapy and intraoperative radiotherapy techniques for two breast cancer cell lines. Acta Oncol 2010; 49(8):1261–12683

3 The START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008; 9: 331–3414

4 Herskind C, Griebel J, Kraus-Tiefenbacher U, Wenz F. Sphere of equivalence—a novel target volume concept for intraoperative radiotherapy using low-energy x rays. Int J Radiat Oncol Biol Phys 2008; 72: 1575–15815

5 Herskind C, Steil V, Kraus-Tiefenbacher U, Wenz F. Radiobiological aspects of intraoperative radiotherapy (IORT) with isotropic low-energy x rays for early-stage breast cancer. Radiat Res 2005; 163: 208–2156

6 Huang J, Barbera L, Brouwers M et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol 2003; 21(3): 555–5637

7 Belletti B, Vaidya JS, D‘Andrea S et al. Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res 2008; 14(5): 1325–13328

8 Vaidya JS. Partial breast irradiation using targeted intraoperative radiotherapy (Targit). Nat Clin Pract Oncol 2007; 4(7): 384–3859

9 Vaidya JS, Tobias JS, Baum M et al. Intraoperative radiotherapy for breast cancer. Lancet Oncol 2004; 5: 165–17310

10 Vaidya JS, Joseph DJ, Tobias JS et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010; 376: 91–10211

11 Poortmans PM, Collette L, Bartelink H et al. The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 „boost versus no boost“ trial. Cancer Radiother 2008; 12(6–7): 565–57012

12 Vaidya JS, Baum M, Tobias JS et al. Efficacy of Targeted Intraoperative Radiotherapy (TARGIT) boost after breast conserving surgery: Updated results. J Clin Oncol 2008; 26: 56513

13 Kuerer HM, Arthur DW, Haffty BG. Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence: The potential role of partial breast irradiation. Cancer 2004, 100: 2269–228014

14 M. Keshtgar, JS Tobias JS Vaidya N. et al. Breast cancer patients treated with intra-operative radiotherapy [IORT] alone when conventional external beam radiation therapy [EBRT] was not possible. J Clin Oncol 2008; 26: Abstract 11517

15 Wenz F, Schneider F, Neumaier C et al. Kypho-IORT – a novel approach of intraoperative radiotherapy during kyphoplasty for vertebral metastases. Radiat Oncol 2010; 5:11

16 Kalapurakal JA, Goldman S, Stellpflug W et al. Phase I study of intraoperative radiotherapy with photon radiosurgery system in children with recurrent brain tumors: preliminary report of first dose level (10 Gy). Int J Radiat Oncol Biol Phys 2006; 65 : 800–808

17 Curry WT, Cosgrove GR, Hochberg FH et al. Stereotactic interstitial radiosurgery for cerebral metastases. J Neurosurg 2005; 103: 630–635

18 Takakura K, Kubo O. Treatment of malignant brain tumors. Gan To Kagaku Ryoho 2000; 27 Suppl 2: 449–53

19 Eljamel MS, Mosely H, Perry J et al. Intraoperative radiosurgery and tumour fluorescence guided resection is associated with long survival in glioblastomas. Poster abstract presented at the AANS annual meeting 2007, Washington DC, USA; Abstract 42176

20 Eljamel MS, Liaguart I, Perry J et al. Intraoperative radiotherapy using mobile miniature X-ray source in malignant brain tumors. Poster abstract presented at the AANS annual meeting 2008, Chicago, USA; Abstract 49067

21 Pantazis G, Trippel M, Birg W et al. Stereotactic interstitial radiosurgery with the Photon Radiosurgery System (PRS) for metastatic brain tumors: a prospective single-center clinical trial Int J Radiat Oncol Biol Phys 2009; 75(5): 1392–1400

22 Rutkowski T, Wygoda A, Hutnik M et al. Intraoperative radiotherapy (IORT) with low-energy photons as a boost in patients with early-stage oral cancer with the indications for postoperative radiotherapy : treatment feasibility and preliminary results. Strahlenther Onkol 2010; 86(9): 496–501

23 Algur E, Mahadevan A, Deibel C et al. Interstitial photon radiosurgery system for re-current and locally advanced rectal cancer: a retrospective review of 24 patients. ASCO Gastrointestinal Cancers Symposium, Jan 27–29, 2005, Hollywood, Florida, USA. Abstract No 208

24 Lyadov KV, Yu A, Sinyakin S, Improvement of curativity of video-assisted surgery for colorectal cancer due to intra-operative contact radiotherapy using the INTRABEAM system. Poster abstract presented at the ISIORT annual meeting 2008, Madrid, Spain

25 Lyadov KV, Krymskiy VA, Yu A et al. Evaluation of safety on intraoperative radiotherapy using the INTRABEAM system in combined treatment of gastric cancer. Poster abstract presented at the ISIORT annual meeting 2008, Madrid, Spain

26 Schneider F, Fuchs H, Lorenz F et al. A novel device for intravaginal electronic brachytherapy. Int J Radiat Oncol Biol Phys; 74(4): 1298–305

27 Bodner WR, Hilaris BS, Alagheband M et al. Use of low-energy X-rays in the treatment of superficial non-melanomatous skin cancers. Cancer Invest 2003; 21(3): 355–362

28 Wenz F, Welzel G, Blank E et al. Intraoperative radiotherapy as a Boost during breast-conserving surgery using low-kilovoltage x-rays: The first 5 years of experience with a novel approach. Int J Radiat Oncol Biol Phys 2010; 77: 1309–1314

29 Kraus-Tiefenbacher U, Bauer L, Scheda A et al. Long-term toxicity of an intraoperative radiotherapy boost using low energy X-rays during breas tconserving surgery. Int J Radiat Oncol Biol Phys 2006; 66(2): 377-381

This page was printed from OSL Web site at